The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260083716A1, filed on September 13, 2023. The application, assigned to The Children's Mercy Hospital, details compositions and methods for treating movement disorders, specifically dystonia, utilizing improved formulations of trihexyphenidyl, with a focus on high chiral purity R-trihexyphenidyl.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for movement disorders. Companies involved in the research, development, or manufacturing of neurological drugs should monitor this patent's progress and consider its implications for their intellectual property and product pipelines.